Company news: Amylin vs. Lilly; CVS Caremark

Share this article:
Amylin was granted a temporary restraining order against Eli Lilly & Co. preventing Lilly from going forward with plans to have the same reps detail both Byetta, which it co-promotes with Amylin, and Boehringer Ingelheim's rival type 2 diabetes drug Tradjenta in the US.

The authors of a study of medication adherence that included researchers from Harvard, Brigham and Women's Hospital and CVS Caremark issued their conclusions, calling for: the development of tools allowing prediction and targeting of patients at-risk for non-adherence and prescription abandonment; adoption of a “pharmacy home” concept to simplify care for patients with complex therapies; individualized counseling by pharmacists and healthcare providers; research on the use of financial and other incentives to encourage adherence; a “personalized medicine” approach for pharmacies through pharmacogenomics or individualized counseling with pharmacists; and the use of social networks to improve adherence through family and friends.  
Share this article:

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.